LLY

1,068.91

-0.6%↓

JNJ

206.38

-0.11%↓

ABBV

225.01

-1.21%↓

UNH

325.65

-1.33%↓

AZN

91.26

-1.59%↓

LLY

1,068.91

-0.6%↓

JNJ

206.38

-0.11%↓

ABBV

225.01

-1.21%↓

UNH

325.65

-1.33%↓

AZN

91.26

-1.59%↓

LLY

1,068.91

-0.6%↓

JNJ

206.38

-0.11%↓

ABBV

225.01

-1.21%↓

UNH

325.65

-1.33%↓

AZN

91.26

-1.59%↓

LLY

1,068.91

-0.6%↓

JNJ

206.38

-0.11%↓

ABBV

225.01

-1.21%↓

UNH

325.65

-1.33%↓

AZN

91.26

-1.59%↓

LLY

1,068.91

-0.6%↓

JNJ

206.38

-0.11%↓

ABBV

225.01

-1.21%↓

UNH

325.65

-1.33%↓

AZN

91.26

-1.59%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

19.21 -3.18

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.91

Максимум

19.79

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
EPS	-0.7
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+87.59% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	588M 1.7B
Предишно отваряне	22.39
Предишно затваряне	19.21

Настроения в новините

By Acuity

50%

167 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.11.2025 г., 15:29 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

30.11.2025 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

30.11.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over U.S. Economy, Japan Earnings -- Market Talk

30.11.2025 г., 22:24 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.11.2025 г., 22:24 ч. UTC

Пазарно говорене

Australian Equities Typically Rise in Year Before Rate Hikes Start -- Market Talk

30.11.2025 г., 07:30 ч. UTC

Придобивния, сливания и поглъщания

Strategy Insiders Kept Buying Preferred Stock as Bitcoin Price Slid -- Barrons.com

28.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 19:59 ч. UTC

Пазарно говорене

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28.11.2025 г., 19:47 ч. UTC

Пазарно говорене

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 17:48 ч. UTC

Пазарно говорене

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28.11.2025 г., 15:51 ч. UTC

Пазарно говорене

Canada Household Spending Edges Lower -- Market Talk

28.11.2025 г., 15:33 ч. UTC

Пазарно говорене

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28.11.2025 г., 15:21 ч. UTC

Пазарно говорене

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28.11.2025 г., 15:13 ч. UTC

Пазарно говорене

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28.11.2025 г., 14:51 ч. UTC

Пазарно говорене

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28.11.2025 г., 14:41 ч. UTC

Пазарно говорене

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28.11.2025 г., 14:37 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28.11.2025 г., 14:20 ч. UTC

Пазарно говорене

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28.11.2025 г., 14:10 ч. UTC

Пазарно говорене

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28.11.2025 г., 13:39 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

87.59% нагоре

12-месечна прогноза

Среден 37.18 USD 87.59%

Висок 56 USD

Нисък 24 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

167 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.